Platelet-derived growth factor pathway inhibitors in ovarian cancer

Jordan Schmitt, Daniela Matei

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Platelet-derived growth factor receptors (PDGFRs) are expressed in 50%-70% of ovarian tumors. Platelet-derived growth factor receptor is present and activated in tumor cells through paracrine and autocrine mechanisms. Normal cells in the stroma, particularly fibroblasts, pericytes, and endothelial cells, also harbor PDGFR. The PDGF-PDGFR pathway governs cancer cell proliferation and survival. Platelet-derived growth factor also modulates the stroma, controls tissue interstitial pressure, and plays a role in angiogenesis. Thus, the use of PDGFR inhibitors as cancer therapeutic agents translates into direct inhibitory effects on tumor cells' growth and indirect effects on the stroma. These effects might include increased delivery of chemotherapy into tumors and antiangiogenic properties induced partly by disruption of the pericytes' function. Imatinib mesylate, sorafenib, dasatinib, sunitinib, and neutralizing PDGFR antibodies are being investigated in clinical trials in patients with recurrent ovarian cancer. Development of molecular predictors of activity should remain a priority during early clinical development.

Original languageEnglish (US)
Pages (from-to)120-126
Number of pages7
JournalClinical Ovarian Cancer
Volume1
Issue number2
DOIs
StatePublished - Dec 2008

Fingerprint

Platelet-Derived Growth Factor Receptors
Platelet-Derived Growth Factor
Ovarian Neoplasms
Neoplasms
Pericytes
Cell Survival
Endothelial Cells
Fibroblasts
Cell Proliferation
Clinical Trials
Pressure
Drug Therapy
Antibodies
Growth

Keywords

  • Fibroblast growth factor
  • Imatinib
  • Pericytes
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Platelet-derived growth factor pathway inhibitors in ovarian cancer. / Schmitt, Jordan; Matei, Daniela.

In: Clinical Ovarian Cancer, Vol. 1, No. 2, 12.2008, p. 120-126.

Research output: Contribution to journalArticle

@article{02936052cc3c41bcbbd8582ccd16f9d9,
title = "Platelet-derived growth factor pathway inhibitors in ovarian cancer",
abstract = "Platelet-derived growth factor receptors (PDGFRs) are expressed in 50{\%}-70{\%} of ovarian tumors. Platelet-derived growth factor receptor is present and activated in tumor cells through paracrine and autocrine mechanisms. Normal cells in the stroma, particularly fibroblasts, pericytes, and endothelial cells, also harbor PDGFR. The PDGF-PDGFR pathway governs cancer cell proliferation and survival. Platelet-derived growth factor also modulates the stroma, controls tissue interstitial pressure, and plays a role in angiogenesis. Thus, the use of PDGFR inhibitors as cancer therapeutic agents translates into direct inhibitory effects on tumor cells' growth and indirect effects on the stroma. These effects might include increased delivery of chemotherapy into tumors and antiangiogenic properties induced partly by disruption of the pericytes' function. Imatinib mesylate, sorafenib, dasatinib, sunitinib, and neutralizing PDGFR antibodies are being investigated in clinical trials in patients with recurrent ovarian cancer. Development of molecular predictors of activity should remain a priority during early clinical development.",
keywords = "Fibroblast growth factor, Imatinib, Pericytes, Tyrosine kinase inhibitors",
author = "Jordan Schmitt and Daniela Matei",
year = "2008",
month = "12",
doi = "10.3816/COC.2008.n.013",
language = "English (US)",
volume = "1",
pages = "120--126",
journal = "Clinical Ovarian Cancer",
issn = "1941-4390",
number = "2",

}

TY - JOUR

T1 - Platelet-derived growth factor pathway inhibitors in ovarian cancer

AU - Schmitt, Jordan

AU - Matei, Daniela

PY - 2008/12

Y1 - 2008/12

N2 - Platelet-derived growth factor receptors (PDGFRs) are expressed in 50%-70% of ovarian tumors. Platelet-derived growth factor receptor is present and activated in tumor cells through paracrine and autocrine mechanisms. Normal cells in the stroma, particularly fibroblasts, pericytes, and endothelial cells, also harbor PDGFR. The PDGF-PDGFR pathway governs cancer cell proliferation and survival. Platelet-derived growth factor also modulates the stroma, controls tissue interstitial pressure, and plays a role in angiogenesis. Thus, the use of PDGFR inhibitors as cancer therapeutic agents translates into direct inhibitory effects on tumor cells' growth and indirect effects on the stroma. These effects might include increased delivery of chemotherapy into tumors and antiangiogenic properties induced partly by disruption of the pericytes' function. Imatinib mesylate, sorafenib, dasatinib, sunitinib, and neutralizing PDGFR antibodies are being investigated in clinical trials in patients with recurrent ovarian cancer. Development of molecular predictors of activity should remain a priority during early clinical development.

AB - Platelet-derived growth factor receptors (PDGFRs) are expressed in 50%-70% of ovarian tumors. Platelet-derived growth factor receptor is present and activated in tumor cells through paracrine and autocrine mechanisms. Normal cells in the stroma, particularly fibroblasts, pericytes, and endothelial cells, also harbor PDGFR. The PDGF-PDGFR pathway governs cancer cell proliferation and survival. Platelet-derived growth factor also modulates the stroma, controls tissue interstitial pressure, and plays a role in angiogenesis. Thus, the use of PDGFR inhibitors as cancer therapeutic agents translates into direct inhibitory effects on tumor cells' growth and indirect effects on the stroma. These effects might include increased delivery of chemotherapy into tumors and antiangiogenic properties induced partly by disruption of the pericytes' function. Imatinib mesylate, sorafenib, dasatinib, sunitinib, and neutralizing PDGFR antibodies are being investigated in clinical trials in patients with recurrent ovarian cancer. Development of molecular predictors of activity should remain a priority during early clinical development.

KW - Fibroblast growth factor

KW - Imatinib

KW - Pericytes

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=77950376241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950376241&partnerID=8YFLogxK

U2 - 10.3816/COC.2008.n.013

DO - 10.3816/COC.2008.n.013

M3 - Article

AN - SCOPUS:77950376241

VL - 1

SP - 120

EP - 126

JO - Clinical Ovarian Cancer

JF - Clinical Ovarian Cancer

SN - 1941-4390

IS - 2

ER -